OMEICOS Ophthalmics

OMEICOS Ophthalmics is a US-based biopharmaceutical subsidiary of OMEICOS Therapeutics, focused on developing first-in-class small molecule therapeutics for severe eye diseases, including wet age-related macular degeneration (wet AMD). The company's technology utilizes synthetic analogs of natural omega-3 fatty acid metabolites, known as epoxyeicosanoids, which activate endogenous cell-protective and anti-inflammatory pathways. Their lead candidate, OMT-28, is an orally available biased modulator of the S1PR1 receptor that promotes mitochondrial function and reduces inflammation. By offering an oral alternative to traditional intravitreal injections, OMEICOS aims to significantly improve the treatment burden and outcomes for patients with retinal disorders.